Authors
Loading...
Targeted metabolomic profiling reveals predictive biomarkers for GVHD risk in allo-HSCT recipients, suggesting improved risk assessment strategies.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: